PainReform Ltd. (NASDAQ:PRFX – Get Free Report) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 2,800 shares, a decline of 96.4% from the August 15th total of 77,000 shares. Based on an average daily volume of 277,500 shares, the days-to-cover ratio is presently 0.0 days.
Wall Street Analysts Forecast Growth
Separately, Maxim Group reissued a “buy” rating and issued a $2.00 price target on shares of PainReform in a research note on Wednesday, June 26th.
View Our Latest Report on PainReform
PainReform Trading Down 12.6 %
PainReform (NASDAQ:PRFX – Get Free Report) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.40) EPS for the quarter.
Hedge Funds Weigh In On PainReform
A hedge fund recently bought a new stake in PainReform stock. Armistice Capital LLC purchased a new position in PainReform Ltd. (NASDAQ:PRFX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 170,000 shares of the company’s stock, valued at approximately $468,000. Armistice Capital LLC owned approximately 10.90% of PainReform at the end of the most recent quarter. Hedge funds and other institutional investors own 37.28% of the company’s stock.
PainReform Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
Featured Stories
- Five stocks we like better than PainReform
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Leveraged ETFs to Multiply Returns
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.